GLP-1 agonists such as semaglutide can cause early worsening with rapid HbA1c falls.
Examine patients with moderate or worse retinopathy more closely when systemic treatment intensifies.
Diabetic retinopathy is treated in the eye, but its course is set by the rest of the body. Two drug stories matter right now: fenofibrate, which the 2024 LENS trial showed slows progression, and GLP-1 receptor agonists such as semaglutide, which can cause early worsening in some patients. Both come up in clinic every week.
The basics first
Glucose: DCCT (type 1) and UKPDS (type 2) established that tight control reduces the onset and progression of retinopathy.
Blood pressure: UKPDS showed tight blood pressure control reduced retinopathy progression and the need for laser.
Early worsening: a rapid, large fall in HbA1c can transiently worsen retinopathy, particularly when it is already moderate or worse. The long-term benefit of control still wins, but these eyes need closer follow-up.
Fenofibrate: three trials to know
Trial
Population
Key retinal finding
FIELD (Lancet 2007)
9,795 people with type 2 diabetes, fenofibrate 200 mg vs placebo
About 30% fewer patients needed first laser treatment for retinopathy
ACCORD Eye (NEJM 2010)
2,856 people with type 2 diabetes, fenofibrate plus simvastatin vs simvastatin alone
Retinopathy progression over 4 years: 6.5% vs 10.2%, about a 40% relative reduction
LENS (NEJM Evidence 2024)
1,151 adults with type 1 or type 2 diabetes and early retinopathy or maculopathy, recruited through Scotland's screening programme. Fenofibrate 145 mg vs placebo for about 4 years.
Referable disease or need for treatment: 22.7% vs 29.2%, a 27% relative reduction. Macular oedema was also reduced, and the benefit was similar in type 1 and type 2 diabetes.
Mechanism: fenofibrate is a PPAR-α agonist. Its retinal benefit seems largely independent of lipid lowering, through anti-inflammatory, anti-apoptotic and vascular effects.
Safety: it causes a reversible rise in serum creatinine, needs dose adjustment in renal impairment, and carries a myopathy risk that is higher with statins. It is not a drug for ophthalmologists to start alone.
In practice: for patients with mild to moderate NPDR or early maculopathy, it is reasonable to write to the physician suggesting fenofibrate be considered. Australia's regulator (TGA) approved it "to slow the progression of existing diabetic retinopathy in patients with type 2 diabetes".
GLP-1 receptor agonists and retinopathy
The signal: in SUSTAIN-6 (NEJM 2016, 3,297 patients), semaglutide was associated with more retinopathy complications than placebo: 3.0% vs 1.8% (HR 1.76). Most events occurred in patients with pre-existing retinopathy and a large, rapid fall in HbA1c, which fits the early-worsening pattern.
Real-world data: an AAO IRIS Registry analysis of more than 48,000 semaglutide users found that only a small proportion of eyes worsened over two years. It had no control group, so it cannot settle the question.
The definitive answer is pending: the FOCUS trial is following eyes on semaglutide with standardised ETDRS grading and is expected to finish around 2027.
Separate issue: semaglutide has also been linked to NAION. See our post on semaglutide and NAION.
A practical approach in clinic
Situation
What to do
Patient about to start a GLP-1 agonist or insulin intensification, with known retinopathy
Dilated baseline examination. If severe NPDR or PDR, review within about 3 months, and consider treating PDR before glucose falls sharply.
Retinopathy worsens soon after HbA1c falls
Treat the eye on its merits (PRP or anti-VEGF). Do not stop the diabetes drug yourself; discuss with the physician.
Mild to moderate NPDR, stable
Reinforce glucose, blood pressure and lipid targets. Suggest the physician consider fenofibrate.
Viva pearls
Fenofibrate works in the eye largely independently of lipid lowering. Explain this as a PPAR-α effect.
LENS was embedded in a national screening programme, which made it pragmatic and large at low cost.
Early worsening is classically described with the start of intensive insulin in DCCT, and also in pregnancy and after bariatric surgery.
SGLT2 inhibitors have been associated with less retinopathy progression in observational studies, but this is not proven in randomised trials.
Patel D. Fenofibrate, GLP-1 Agonists and Diabetic Retinopathy: What Residents Should Know. RPC Rounds (Sadbhaav Eye Clinic). Updated October 2026. Available at: https://www.sadbhaavclinic.com/systemic-drugs-diabetic-retinopathy.html. Accessed [date].
Written and medically reviewed by Dr. Dhaval Patel, MD (Ophthalmology, AIIMS New Delhi) · Editorial policy